Effects of kratom on driving: Results from a cross-sectional survey, ecological momentary assessment, and pilot simulated driving Study

References

• Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. 2020. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: a Randomized Clinical Trial. JAMA. 324(21):2177–2186. doi:10.1001/jama.2020.21218.
   PubMed Web of Science ®Google Scholar
• Babu KM, McCurdy CR, Boyer EW. 2008. Opioid receptors and legal highs: salvia divinorum and Kratom. Clin Toxicol. 46(2):146–152. doi:10.1080/15563650701241795.
   PubMed Web of Science ®Google Scholar
• Berthold EC, Kamble SH, Raju KS, Kuntz MA, Senetra AS, Mottinelli M, León F, Restrepo LF, Patel A, Ho NP, et al. 2022. The lack of contribution of 7-hydroxymitragynine to the antinociceptive effects of mitragynine in mice: a pharmacokinetic and pharmacodynamic study. Drug Metab Dispos. 50(2):158–167. doi:10.1124/dmd.121.000640.
   PubMed Web of Science ®Google Scholar
• Brooks-Russell A, Brown T, Friedman K, Wrobel J, Schwarz J, Dooley G, Ryall KA, Steinhart B, Amioka E, Milavetz G, et al. 2021. Simulated driving performance among daily and occasional cannabis users. Accid Anal Prev. 160:106326. doi:10.1016/j.aap.2021.106326.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 28(2):193–213. doi:10.1016/0165-1781(89)90047-4.
   PubMed Web of Science ®Google Scholar
• Colonna R, Hand CL, Holmes JD, Alvarez L. 2021. Young drivers’ determinants of driving under the influence of cannabis: findings from the Youth Cannabis and Driving Survey (YouCanDS). J Safety Res. 78:229–241. doi:10.1016/j.jsr.2021.05.001.
   PubMed Web of Science ®Google Scholar
• Freydier C, Berthelon C, Bastien-Toniazzo M, Gineyt G. 2014. Divided attention in young drivers under the influence of alcohol. J Safety Res. 49:13–18. doi:10.1016/j.jsr.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. 2020. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 208:107849. doi:10.1016/j.drugalcdep.2020.107849.
   PubMed Web of Science ®Google Scholar
• Grundmann O. 2017. Patterns of kratom use and health impact in the US—results from an online survey. Drug Alcohol Depend. 176:63–70.
   PubMed Web of Science ®Google Scholar
• Grundmann O, Veltri CA, Morcos S, Smith KE, Singh D, Corazza O, Cinosi E, Martinotti G, Walsh Z, Swogger MT. 2023. Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey. Exp Clin Psychopharmacol. 31:(5):963–977.
   PubMed Web of Science ®Google Scholar
• Henningfield JE, Wang DW, Huestis MA. 2022. Kratom abuse potential 2021: an updated eight factor analysis. Front Pharmacol. 12:775073. doi:10.3389/fphar.2021.775073.
   PubMed Web of Science ®Google Scholar
• Hiranita T, Obeng S, Sharma A, Wilkerson JL, McCurdy CR, McMahon LR. 2022. In vitro and in vivo pharmacology of kratom. Adv Pharmacol. 93:35–76. doi:10.1016/bs.apha.2021.10.001.
   PubMedGoogle Scholar
• Ingsathit A, Woratanarat P, Anukarahanonta T, Rattanasiri S, Chatchaipun P, Wattayakorn K, Lim S, Suriyawongpaisal P. 2009. Prevalence of psychoactive drug use among drivers in Thailand: a roadside survey. Accid Anal Prev. 41(3):474–478. PMID:19393795 doi:10.1016/j.aap.2009.01.010.
   PubMed Web of Science ®Google Scholar
• Kamble SH, Berthold EC, King TI, Raju Kanumuri SR, Popa R, Herting JR, León F, Sharma A, McMahon LR, Avery BA, et al. 2021. Pharmacokinetics of eleven kratom alkaloids following an oral dose of either traditional or commercial kratom products in rats. J Nat Prod. 84(4):1104–1112. doi.org/,. doi:10.1021/acs.jnatprod.0c01163.PMID: 33620222
   PubMed Web of Science ®Google Scholar
• Kelley-Baker T, Berning A, Ramirez A, Lacey JH, Carr K, Waehrer G, Moore C, Pell K, Yao J, Compton RP. 2017. 2013–2014 National Roadside Study of alcohol and drug use by drivers: drug results. United States Natl Highway Traffic Safety Admin.
   Google Scholar
• Knoy JL, Peterson BL, Couper FJ. 2014. Suspected impaired driving case involving α-pyrrolidinovalerophenone, methylone and ethylone. J Anal Toxicol. 38(8):615–617. doi:10.1093/jat/bku073.
   PubMed Web of Science ®Google Scholar
• Kubinec R. 2022. Ordered Beta Regression: a Parsimonious, Well-Fitting Model for Continuous Data with Lower and Upper Bounds. Polit Anal. 31(4):519–536. doi:10.1017/pan.2022.20.
   Web of Science ®Google Scholar
• Leksungnoen N, Andriyas T, Ngernsaengsaruay C, Uthairatsamee S, Racharak P, Sonjaroon W, Kjelgren R, Pearson BJ, McCurdy CR, Sharma A.,. 2022. Variations in mitragynine content in the naturally growing Kratom (Mitragyna speciosa) population of Thailand. Front Plant Sci. 13:1028547. doi:10.3389/fpls.2022.1028547.
   PubMed Web of Science ®Google Scholar
• Leisch F. 2004. FlexMix: a General Framework for Finite Mixture Models and Latent Class Regression in R. J Stat Soft. 11(8):1–18. doi:10.18637/jss.v011.i08.
   Google Scholar
• Lenth RV. 2021. emmeans: Estimated Marginal Means, aka Least-Squares Means. https://CRAN.R-project.org/package=emmeans
   Google Scholar
• Miller RE, Brown TL, Lee S, Tibrewal I, Gaffney GG, Milavetz G. 2020. Impact of cannabis and low alcohol concentration on divided attention tasks during driving. Traffic Inj Prev. 221(sup1)S123–S129. doi:10.1080/15389588.2020.1814956.
   Google Scholar
• Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ-Y, Ramanathan S, Sharma A, León F, et al. 2019. Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids. J Med Chem. 63(1):433–439. doi:10.1021/acs.jmedchem.9b01465.
   PubMed Web of Science ®Google Scholar
• Obeng S, Leon F, Patel A, Gonzalez JDZ, Da Silva LC, Restrepo LF, Hiranita T. 2022. Interactive Effects of µ-Opioid and Adrenergic-α2 Receptor Agonists in Rats: pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine. J Pharmacol Exp Ther. 383(3):182–198. doi:10.1124/jpet.122.001192.
   PubMed Web of Science ®Google Scholar
• Owsley C, Stalvey B, Wells J, Sloane ME. 1999. Older drivers and cataract: driving habits and crash risk. J Gerontol A Biol Sci Med Sci. 54(4):M203–M211. doi:10.1093/gerona/54.4.M203.
   PubMed Web of Science ®Google Scholar
• Ronen A, Chassidim HS, Gershon P, Parmet Y, Rabinovich A, Bar-Hamburger R, Cassuto Y, Shinar D.,. 2010. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prev. 42(6):1855–1865. doi:10.1016/j.aap.2010.05.006.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kamble SH, León F, Chear NJ, King TI, Berthold EC, Ramanathan S, McCurdy CR, Avery BA.,. 2019. Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra‐performance liquid chromatography − tandem mass spectrometry. Drug Test Anal. 11(8):1162–1171. doi:10.1002/dta.2604.
   PubMed Web of Science ®Google Scholar
• Smith KE, Lawson T. 2017. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 180:340–348. doi:10.1016/j.drugalcdep.2017.08.034.
   PubMed Web of Science ®Google Scholar
• Smith KE, Dunn KE, Rogers JM, Garcia-Romeu A, Strickland JC, Epstein DH. 2022. Assessment of kratom use disorder and withdrawal among an online convenience sample of US adults. J Addict Med. 16(6):666–670. doi:10.1097/ADM.0000000000000986.
   PubMed Web of Science ®Google Scholar
• Smith KE, Dunn KE, Rogers JM, Grundmann O, McCurdy CR, Garcia-Romeu A, Schriefer D, Swogger MT, Epstein DH. 2022. Kratom use as more than a “self-treatment. Am J Drug Alcohol Abuse. 48(6):684–694. doi:10.1080/00952990.2022.2083967.
   PubMed Web of Science ®Google Scholar
• Smith KE, Feldman JD, Dunn KE, McCurdy CR, Weiss ST, Grundmann O, Garcia-Romeu A, Epstein DH. 2023. Examining the paradoxical effects of kratom: a narrative inquiry. Fron Pharma. 14:1174.
   Google Scholar
• Smith KE, Feldman JD, Dunn KE, McCurdy CR, Grundmann O, Garcia-Romeu A, Panlilio LV, Rogers JM, Sharma A, Pont-Fernandez S, et al. 2023. Novel methods for the remote investigation of emerging substances: Application to kratom. Exp Clin Psychopharmacol.
   Google Scholar
• Smith KE, Feldman JD, Schriefer D, Weiss ST, Grundmann O, Dunn KE, Singh D, McCurdy CR, Butera G, Epstein DH, et al. 2023. Diagnostic ambiguities and underuse of clinical assessment tools: a systematic review of case reports on kratom addiction and physical dependence. Curr Addict Rep. 10(2):282–292. doi:10.1007/s40429-023-00474-7.
   Google Scholar
• Smith KE, Panlilio LV, Feldman JD, Grundmann O, Dunn KE, McCurdy CR, Garcia-Romeu A, Epstein DH. 2024. Ecological momentary assessment of self-reported kratom use, effects, and motivations among US adults. JAMA Netw Open. 7(1):e2353401. doi:10.1001/jamanetworkopen.2023.53401.
   PubMed Web of Science ®Google Scholar
• Smith KE, Rogers JM, Schriefer D, Grundmann O. 2021. Therapeutic benefit with caveats?: analyzing social media data to understand the complexities of kratom use. Drug Alcohol Depend. 226:108879. doi:10.1016/j.drugalcdep.2021.108879.
   PubMed Web of Science ®Google Scholar
• Smith KE, Rogers JM, Dunn KE, Grundmann O, McCurdy CR, Schriefer D, Epstein DH. 2022. Searching for a signal: self-reported Kratom dose-effect relationships among a sample of US adults with regular Kratom use histories. Front Pharmacol. 13:445. doi:10.3389/fphar.2022.765917.
   Web of Science ®Google Scholar
• Smith KE, Rogers JM, Sharma A, McCurdy CR, Weiss ST, Dunn KE, Feldman JD, Kuntz MA, Mukhopadhyay S, Raju KSR, et al. 2023. Reponses to a “typical” morning dose of kratom in people who use kratom regularly: A direct-observation study. J Addict Med. doi:10.1097/ADM.0000000000001259.
   Google Scholar
• Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, Parkhurst KA, Priddy BM, Walsh Z. 2015. Experiences of Kratom Users: A Qualitative Analysis. J Psychoactive Drugs. 47(5):360–367. doi:10.1080/02791072.2015.1096434.
   PubMed Web of Science ®Google Scholar
• Tanna RS, Nguyen JT, Hadi DL, Manwill PK, Flores-Bocanegra L, Layton ME, White JR, Cech NB, Oberlies NH, Rettie AE, et al. 2022. Clinical pharmacokinetic assessment of kratom (mitragyna speciosa), a botanical product with opioid-like effects, in healthy adult participants. Pharmaceutics. 14(3):620. doi:10.3390/pharmaceutics14030620.
   PubMed Web of Science ®Google Scholar
• Veldstra JL, Bosker WM, de Waard D, Ramaekers JG, Brookhuis KA. 2015. Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research. Psychopharmacology. 232(16):2911–2919. PMID: 25957748 doi:10.1007/s00213-015-3927-9.
   PubMed Web of Science ®Google Scholar
• Wickham H. 2016. ggplot2: elegant Graphics for Data Analysis. New York: Springer-Verlag.
   Google Scholar
• Wright TH. 2018. Suspected driving under the influence case involving mitragynine. J Anal Toxicol. 42(7):e65–e68. doi:10.1093/jat/bky028.
   PubMed Web of Science ®Google Scholar
• Zamarripa CA, Novak MD, Weerts EM, Vandrey R, Spindle TR. 2022. The effects of oral and vaporized cannabis alone, and in combination with alcohol, on driving performance using the STISIM driving simulator: A two-part, double-blind, double-dummy, placebo-controlled, randomized crossover clinical laboratory protocol. Front Pharmacol. 13:964749. doi:10.3389/fphar.2022.964749.
   PubMedGoogle Scholar